Investigational New Drugs

Preclinical antitumor activity of XK469 (NSC 656889)
pp. 287-296(10)
Authors: M LoRusso P.; Parchment R.; Demchik L.; Knight J.; Polin L.; Dzubow J.; Behrens C.; Harrison B.; Trainor G.; Corbett T.H.

Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo
pp. 297-302(6)
Authors: Pastrone I.; Viale M.; Cafaggi S.; Mariggiò M.A.; Parodi A.; Esposito M.

Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations
pp. 303-313(11)
Authors: Shalinksy D.R.; Brekken J.; Zou H.; Kolis S.; Wood A.; Webber S.; Appelt K.

Pala Versus Streptozotocin, Doxorubicin, and Meccnu in the Treatment of Patients With Advanced Pancreatic Carcinoma
pp. 315-318(4)
Authors: Witte R.S.; Ryan L.M.; Schutt A.J.; Carbone P.P.; Engstrom P.F.

Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
pp. 319-324(6)
Authors: Rassmann I.; Thödtmann R.; Thödtmann R.; Mross M.; Hüttmann A.; Berdel W.E.; Manegold C.; Fiebig H.H.; Kaeser-Fröhlich A.; Burk K.; Hanauske A.-R.; Hanauske A.-R.

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
pp. 325-330(6)
Authors: Berlin J.D.; Alberti D.B.; Arzoomanian R.Z.; Feierabend C.A.; Simon K.J.; Binger K.A.; Marnocha R.M.; Wilding G.

Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study
pp. 331-332(2)
Authors: Taylor S.A.; Giroux D.J.; Jaeckle K.A.; Panella T.J.; Dakhil S.R.; Schold S.C.

Oral etoposide for patients with advanced adenocarcinoma of the pancreas
pp. 333-335(3)
Authors: Thomas E.; Dumas P.; Ajani J.A.

A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma
pp. 337-340(4)
Authors: Berg W.J.; McCaffrey J.; Schwartz L.H.; Mariani T.; Mazumdar M.; Motzer R.J.; Motzer R.J.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma
pp. 341-346(6)
Authors: Pazdur R.; Medgyesy D.C.; Winn R.J.; Dakhil S.R.; Moore Jr. D.F.; Scalzo A.; Hoff P.M.; Arbuck S.G.; Abbruzzese J.L.

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)
pp. 347-351(5)
Authors: Meyers F.J.; Lew D.; Lara Jr. P.N.; Williamson S.; Marshall E.; Balcerzak S.P.; Rivkin S.E.; Samlowski W.; Crawford E.D.

A phase II trial of irinotecan in hormone-refractory prostate cancer
pp. 353-359(7)
Authors: Reese D.M.; Tchekmedyian S.; Chapman Y.; Prager D.; Rosen P.J.

Contents Volume 16, 1998
pp. 361-366(6)

Instructions for authors
pp. 367-368(2)